We are pleased to announce that Dr Katarzyna Taylor from the Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, has been awarded a 2026 Early Career Grant from the Myotonic Dystrophy Foundation (MDF).
Dr Taylor’s research focuses on the molecular mechanisms underlying myotonic dystrophy type 1 (DM1), with particular emphasis on therapeutic development and MBNL-regulated physiological processes. Her current project, “Mechanisms of MBNL Regulation: Molecular Targets for Potential Therapeutic Intervention in DM1”, aims to identify regulatory mechanisms controlling MBNL1 and MBNL2 expression and to uncover new targets for therapy.
Over the course of her scientific career, Dr Taylor has investigated antisense oligonucleotides, small molecules, and repurposed antibiotics in the context of toxic RNA biology, and has contributed to studies on the role of MBNL proteins in development and disease. MDF also highlights her current position as Assistant Professor and principal investigator of a SONATA grant, as well as her involvement in the European ENTRY-DM consortium.
This distinction is an important international recognition of research conducted at our Institute and a valuable contribution to ongoing efforts to better understand and develop future therapies for myotonic dystrophy.
Read more:
Myotonic Dystrophy Foundation – 2026 Grant Recipient Feature: Katarzyna Taylor, PhD https://myotonic.org/2026-grant-recipient-feature-katarzyna-taylor-phd/
